Viatris Completes $36.50-a-Share Pacira BioSciences Acquisition, Expects $90 Million to $100 Million in 2026 Revenue From the Deal
Viatris now owns Pacira BioSciences. The generic and specialty drugmaker said Tuesday it closed its takeover of the non-opioid pain management company, wrapping up a deal first announced on Oct. 8, according to an 8-K filed with the SEC.
Viatris paid $36.50 per Pacira share in cash. The company estimated the total amount paid in the tender offer and follow-on merger at $1.69 billion, excluding related fees and expenses, and said it is funding the purchase through a combination of cash on hand and short-term borrowings.
How the deal closed
Viatris' purchaser subsidiary launched the tender offer on Oct. 30, and it expired one minute after 11:59 p.m. Eastern Time on Nov. 16. The depositary reported that 32,929,780 shares were validly tendered and not withdrawn, which Viatris put at 66.46% of Pacira's outstanding shares, the filing says.
That cleared the deal's minimum condition. On Nov. 17, Viatris accepted the tendered shares for payment and merged the subsidiary into Pacira without a Pacira stockholder vote, under Section 251(h) of Delaware corporate law. Pacira survives as a wholly owned Viatris subsidiary, and shares that were not tendered were converted into the right to receive the same $36.50 in cash.
Pacira's shares will be delisted from the Nasdaq Global Select Market, according to the press release.
What Viatris expects
Viatris said it expects the acquisition to contribute total revenues of $90 million to $100 million for the rest of 2026, covering Nov. 17 through Dec. 31.
"Today marks an important milestone in the execution of our strategy to strengthen our U.S. innovative medicines business," Chief Executive Officer Scott A. Smith said in the release. He said the combination aims to "establish a leadership position in non-opioid pain management."
By the numbers
- Price per Pacira share: $36.50 in cash
- Estimated total payout: $1.69 billion, excluding fees and expenses, the company said
- Shares tendered: 32,929,780
- Expected revenue contribution, Nov. 17 to Dec. 31, 2026: $90 million to $100 million
- Funding: cash on hand and short-term borrowings
Sources
- Form 8-K, Viatris Inc., filed Nov. 17, 2026, Items 2.01 and 7.01 and Exhibit 99.1 press release, accession 0001140361-26-044356
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence. SI may make mistakes.